AbbVie Inc. (TSX:ABBV)
Canada · Delayed Price · Currency is CAD | Market Cap | 493.42B +12.1% |
| Revenue (ttm) | 87.69B +9.5% |
| Net Income | 5.02B -13.3% |
| EPS | 2.83 -13.2% |
| Shares Out | n/a |
| PE Ratio | 98.33 |
| Forward PE | 13.73 |
| Dividend | 1.19 (4.16%) |
| Ex-Dividend Date | Apr 15, 2026 |
| Volume | 2,000 |
| Average Volume | 9,877 |
| Open | 27.73 |
| Previous Close | 27.71 |
| Day's Range | 27.73 - 28.36 |
| 52-Week Range | 25.35 - 34.48 |
| Beta | n/a |
| RSI | 45.04 |
| Earnings Date | Apr 29, 2026 |
About AbbVie
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medi... [Read more]
Financial Performance
In 2025, AbbVie's revenue was $61.16 billion, an increase of 8.57% compared to the previous year's $56.33 billion. Earnings were $4.19 billion, a decrease of -1.23%.
Financial numbers in USD Financial StatementsNews
Allergan Aesthetics Launches Philanthropic Effort in Recognition of Skin Cancer Awareness Month
Through its loyalty rewards program Allē, Allergan Aesthetics will donate to The Skin Cancer Foundation $10 for every new member who joins from a referral in May, up to $100,000. IRVINE, Calif.
AbbVie Thanks 'Excellent Start To 2026' To Immunology And Neuroscience Strength
AbbVie Inc. (NYSE:ABBV) on Wednesday reported first-quarter 2026 sales of $15.00 billion, beating the consensus of $14.72 billion.
AbbVie Earnings Call Transcript: Q1 2026
First quarter 2026 results surpassed expectations with 12.4% revenue growth and strong performance in immunology and neuroscience. Full-year guidance was raised, pipeline progress continued, and significant investments in manufacturing and R&D were announced.
AbbVie Raises FY Guidance on Immunology, Neuroscience Growth
AbbVie raised its full-year adjusted earnings guidance and reported higher first-quarter revenue, boosted by growth in its immunology and neuroscience portfolios.
AbbVie tops quarterly expectations as newer immunology drugs offset Humira decline
AbbVie on Wednesday reported better-than-expected quarterly revenue and profit, fueled by demand for newer immunology drugs Skyrizi and Rinvoq, as the drugmaker continues to navigate its transition a...
AbbVie Reports First-Quarter 2026 Financial Results
Reports First-Quarter Diluted EPS of $0.39 on a GAAP Basis, a Decrease of 45.8 Percent; Adjusted Diluted EPS of $2.65, an Increase of 7.7 Percent; These Results Include an Unfavorable Impact of $0.41 ...
AbbVie Submits Application to FDA for Upadacitinib (RINVOQ®) for Adults and Adolescents with Severe Alopecia Areata
Submission is supported by data from the Phase 3 UP-AA clinical program in which upadacitinib achieved the primary endpoint of severity of alopecia tool (SALT) score ≤ 20 at week 24, with additional e...
EvolveImmune Therapeutics Announces Achievement of Preclinical Milestone in Collaboration with AbbVie
BRANFORD, Conn., April 28, 2026 (GLOBE NEWSWIRE) -- EvolveImmune Therapeutics, a clinical-stage immuno-oncology company developing a new class of multi-specific T cell engagers with integrated CD2 cos...
AbbVie Submits Regulatory Application to FDA for SKYRIZI® (risankizumab-rzaa) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease
Submission supported by data from Phase 3 pivotal AFFIRM study If approved, adult Crohn's disease patients will have an additional option for induction of risankizumab-rzaa which is already approved f...
US FDA declines to approve AbbVie's wrinkle treatment
AbbVie said on Thursday the U.S. Food and Drug Administration has declined to approve its experimental wrinkle treatment, citing issues in manufacturing.
AbbVie Provides Update on TrenibotulinumtoxinE (TrenibotE) Biologics License Application in the U.S.
U.S. Food and Drug Administration (FDA) issues Complete Response Letter (CRL) for trenibotulinumtoxinE (TrenibotE) related to manufacturing processes; no additional clinical studies are requested As t...
AbbVie to build $1.4 billion manufacturing campus in North Carolina
AbbVie will invest $1.4 billion to build a manufacturing campus in North Carolina, the drugmaker said on Wednesday, marking its biggest investment to date in a single site.
AbbVie Selects North Carolina for New $1.4 Billion Manufacturing Campus
Marks AbbVie's largest-ever capital investment in a single campus since its inception Investment demonstrates continued progress against AbbVie's $100 billion commitment to U.S. research and developme...
Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases
Tokyo, Japan and Cambridge and London, UK, 20 April 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that it has reached a third R&D milestone under its multi-target discov...
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...
Erin Lichy Gets Real About Her Natrelle® Breast Augmentation
The entrepreneur and mother of four shares her breast augmentation journey, from consultation to post-op, with Natrelle ® breast implants. As a champion of authenticity, Lichy hopes her transparency w...
Haisco Enters into Exclusive License Agreement with AbbVie to Develop Novel Medicines for Pain
BEIJING, April 13, 2026 /PRNewswire/ -- On April 10, 2026, Haisco Pharmaceutical Group Co., Ltd. (Ticker Code: 002653) announced that it has entered into an exclusive licensing agreement with AbbVie (...
AbbVie Showcases Late‑Breaking Phase 2 Data for Mirvetuximab Soravtansine-gynx (ELAHERE®) in Platinum‑Sensitive Ovarian Cancer (PSOC) at SGO 2026
Results from the Phase 2 IMGN853-0420 trial show an objective response rate of 62.7% and consistent safety findings with mirvetuximab soravtansine-gynx (ELAHERE ®) plus carboplatin followed by a cont...
AbbVie files lawsuit to address 'outdated' drug discount eligibility program
AbbVie has filed a lawsuit against the U.S. government, seeking clearer guidance on patients eligible for a drug discount program.
BOTOX® Cosmetic (onabotulinumtoxinA) Empowers Women Entrepreneurs Through "The Confidence Collective" for Fourth Year
Applications Are Open Now Through April 29 for Entrepreneurs to Apply and Further Unlock Their Potential. Since 2023, the Brand Has Awarded $1.2M to Grant Winners to Boost Their Businesses.
The price Americans pay for medicine has gotten horribly out of control. Here's how to fix it.
More than 300,000 Americans use a medication called Humira. Most of them are paying far too much for it.
Allergan Aesthetics Third State-of-the-Art AMI Center Opens in Austin
The Allergan Medical Institute (AMI) Austin location strengthens the national training network with comprehensive, hands-on education. The Orange County and Atlanta AMI centers continue delivering bes...
Swiss industry body says US tariffs on pharmaceuticals will harm patients
U.S. President Donald Trump's 100% tariffs on the pharmaceutical industry threaten global production, supply chains and ultimately will harm patients, Switzerland's pharmaceutical association interph...
